Copyright © 2004 by the Johns Hopkins Bloomberg School of Public Health
HUMAN GENOME EPIDEMIOLOGY (HuGE) REVIEW |
CYP3A4 Polymorphisms—Potential Risk Factors for Breast and Prostate Cancer: A HuGE Review
1 Molecular Epidemiology Team, Toxicology and Molecular Biology Branch, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Morgantown, WV.
2 Biostatistics and Epidemiology Branch, Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Morgantown, WV.
The steroid hydroxylase CYP3A4 is the most abundant P-450 enzyme in the human liver, and CYP3A enzymes metabolize more than 50% of prescription drugs. The CYP3A4 gene is expressed in the liver, gut, colon, prostate, and breast. Individual variation in CYP3A4 may play a role in breast and prostate carcinogenesis through modulation of sex hormone metabolite levels. Alternatively, CYP3A4 can metabolically activate exogenous carcinogens. CYP3A4 activity varies widely in humans, and more than 78 DNA sequence polymorphisms are known. These observations prompted the hypothesis that variant CYP3A4 may be involved in breast and prostate cancer. Two epidemiologic studies of breast cancer and five of prostate cancer examined CYP3A4 genotypes. A US study showed that inheritance of CYP3A4*1B correlates with early menarche, a breast cancer risk factor. However, an Australian breast cancer case-control study found no association with CYP3A4*1B. Two Scottish prospective studies showed CYP3A4*1B to be a risk factor for prostate cancer among men with benign prostatic hyperplasia. Three other studies were undertaken in the United States: two were case-only studies and the other was a case-sibling control study. Although results for African Americans were inconsistent, these studies suggested that CYP3A4*1B was associated with markers of advanced disease. These observations support the notion that development of robust, conventional molecular epidemiologic case-control studies to address these questions, including gene-gene and gene-environment interactions, will be timely.
breast neoplasms; CYP3A4; cytochrome P-450 enzyme system; epidemiology; genetics; hormones; metabolism; prostatic neoplasms
Abbreviations: Abbreviations: CI, confidence interval; CYP3A4, the gene coding for the cytochrome P-450 enzyme designated CYP3A4; OR, odds ratio; PCR, polymerase chain reaction; UTR, untranslated region.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. He, Q. Cheng, and W. Xie Minireview: Nuclear Receptor-Controlled Steroid Hormone Synthesis and Metabolism Mol. Endocrinol., January 1, 2010; 24(1): 11 - 21. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Sierra Diaz, J. Sanchez Corona, R. C. Rosales Gomez, S. A. Gutierrez Rubio, J. G. Vazquez Camacho, H. Solano Moreno, and M. C. Moran Moguel Angiotensin-converting enzyme insertion/deletion and angiotensin type 1 receptor A1166C polymorphisms as genetic risk factors in benign prostatic hyperplasia and prostate cancer Journal of Renin-Angiotensin-Aldosterone System, December 1, 2009; 10(4): 241 - 246. [Abstract] [PDF]
|
|
|
|
 |
|
 Y. Yamada, N. Metoki, H. Yoshida, K. Satoh, K. Kato, T. Hibino, K. Yokoi, S. Watanabe, S. Ichihara, Y. Aoyagi, et al. Genetic Factors for Ischemic and Hemorrhagic Stroke in Japanese Individuals Stroke, August 1, 2008; 39(8): 2211 - 2218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. R. Rebbeck, A. B. Troxel, S. Norman, G. Bunin, A. DeMichele, R. Schinnar, J. A. Berlin, and B. L. Strom Pharmacogenetic Modulation of Combined Hormone Replacement Therapy by Progesterone-Metabolism Genotypes in Postmenopausal Breast Cancer Risk Am. J. Epidemiol., December 15, 2007; 166(12): 1392 - 1399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Chu, A. Fyles, E. M. Sellers, D. R. McCready, J. Murphy, T. Pal, and S. A. Narod Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use Carcinogenesis, October 1, 2007; 28(10): 2139 - 2142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Biggs, J. Wan, N. S. Cutler, J. Hakkola, P. Uusimaki, H. Raunio, and G. S. Yost Transcription Factor Binding to a Putative Double E-Box Motif Represses CYP3A4 Expression in Human Lung Cells Mol. Pharmacol., September 1, 2007; 72(3): 514 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. L. Nock, D. Tang, A. Rundle, C. Neslund-Dudas, A. T. Savera, C. H. Bock, K. G. Monaghan, A. Koprowski, N. Mitrache, J. J. Yang, et al. Associations between Smoking, Polymorphisms in Polycyclic Aromatic Hydrocarbon (PAH) Metabolism and Conjugation Genes and PAH-DNA Adducts in Prostate Tumors Differ by Race Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1236 - 1245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Estes, K. H. Busse, and S. R. Penzak Pharmacogenetic Considerations in the Management of HIV Infection Journal of Pharmacy Practice, June 1, 2007; 20(3): 234 - 245. [Abstract] [PDF]
|
|
|
|
|
|
Y.-L. Low, A. M. Dunning, M. Dowsett, E. Folkerd, D. Doody, J. Taylor, A. Bhaniani, R. Luben, K.-T. Khaw, N. J. Wareham, et al. Phytoestrogen Exposure Is Associated with Circulating Sex Hormone Levels in Postmenopausal Women and Interact with ESR1 and NR1I2 Gene Variants Cancer Epidemiol. Biomarkers Prev., May 1, 2007; 16(5): 1009 - 1016. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Park, L. Chen, L. Ratnashinge, T. A. Sellers, J.-P. Tanner, J.-H. Lee, N. Dossett, N. Lang, F. F. Kadlubar, C. B. Ambrosone, et al. Deletion Polymorphism of UDP-Glucuronosyltransferase 2B17 and Risk of Prostate Cancer in African American and Caucasian Men. Cancer Epidemiol. Biomarkers Prev., August 1, 2006; 15(8): 1473 - 1478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-J. Liu, P.-L. Huang, Y.-F. Chang, Y.-H. Chen, Y.-H. Chiou, Z.-L. Xu, and R.-H. Wong GSTP1 Genetic Polymorphism Is Associated with a Higher Risk of DNA Damage in Pesticide-Exposed Fruit Growers. Cancer Epidemiol. Biomarkers Prev., April 1, 2006; 15(4): 659 - 666. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Obligacion, M. Murray, and I. Ramzan Drug-Metabolizing Enzymes and Transporters: Expression in the Human Prostate and Roles in Prostate Drug Disposition J Androl, March 1, 2006; 27(2): 138 - 150. [Full Text] [PDF]
|
|